Hepatitis C virus seroprevalence among patients enrolled at the opioid substitution therapy center in Bihar: A cross-sectional study

被引:0
作者
Kumar, Ashish [1 ]
Mahajan, Hemant [1 ,2 ]
Chaturvedi, Sanjay [1 ]
Kumar, Ashok [1 ]
Kumar, Shiril [1 ]
Sahoo, Ganesh Chandra [1 ]
Das, Vidya Nand Rabi [1 ]
Pandey, Krishna [1 ]
机构
[1] Indian Council Med Res, Rajendra Mem Res Inst Med Sci, Patna, India
[2] Indian Council Med Res, Natl Inst Nutr, Dept Publ Hlth Nutr, Hyderabad, Telangana, India
来源
PLOS ONE | 2023年 / 18卷 / 06期
关键词
INJECTION-DRUG USERS; COMPENSATED CIRRHOSIS; RISK-FACTORS; HCV; PREVALENCE; INFECTION; PEOPLE; COHORT;
D O I
10.1371/journal.pone.0287333
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background and aim Hepatitis C virus (HCV) infection poses a major public health challenge in Indian settings due to its huge population and easy transmissibility of HCV among individuals who inject drugs (PWID, which is increasing in India). The National AIDS Control Organization (NACO), India has started the Opioid Substitution Therapy (OST) centers to improve the health status of opioid dependent PWID and prevent the spread of HIV/AIDS among them. We conducted a cross-sectional study to find out the HCV sero-positive status and associated determinants in patients attending the OST centre in the ICMR-RMRIMS, Patna. Materials and methods We utilized the routinely collected (as a part of the National AIDS Control Program) and de-identified data from the OST center from 2014 to 2022 (N = 268). We abstracted the information for exposure variables (such as socio-demographic features and drug history) and outcome variable (HCV serostatus). The association of exposure variables with HCV serostatus was examined using robust Poisson regression. Results All the enrolled participants were male and the prevalence of HCV seropositivity was 28% [95% confidence interval (CI): 22.7% - 33.8%)]. There was a rising prevalence of HCV seropositivity with number of years of injection use (p-trend <0.001) and age (p-trend 0.025). Approximately, 6.3% participants were injecting drugs for >10 years and reported the maximum prevalence of HCV seropositivity (47.1%, 95% CI: 23.3%-70.8%). In adjusted analyses, being employed compared to unemployed patients [adjusted prevalence ratio (aPR) = 0.59; 95% CI: 0.38-0.89]; graduated patients compared to illiterate patients [aPR = 0.11; 95% CI: 0.02-0.78]; and patients with education up to higher secondary compared to illiterate patients [aPR = 0.64; 95% CI: 0.43-0.94] had significantly lesser HCV seropositivity. A-one year increase in injection use [aPR = 1.07; 95% CI: 1.04-1.10] was associated with 7% higher prevalence of HCV seropositivity. Conclusions In this OST center-based study of 268 PWIDs residing in Patna, similar to 28% of patients were HCV seropositive, which was positively associated with years of injection use, unemployment, and illiteracy. Our findings suggest that OST centers offer an opportunity to reach a high-risk difficult to reach group for HCV infection and thus support the notion of integrating HCV care into the OST or de-addiction centres.
引用
收藏
页数:11
相关论文
共 19 条
  • [1] Ambekar A., 2019, MAGNITUDE SUBSTANCE
  • [2] Hepatitis C virus infection in injection drug users in Bavaria: Risk factors for seropositivity
    Markus Backmund
    Kirsten Meyer
    Martin Wächtler
    Dieter Eichenlaub
    [J]. European Journal of Epidemiology, 2003, 18 (6) : 563 - 568
  • [3] Alternatives for logistic regression in cross-sectional studies: An empirical comparison of models that directly estimate the prevalence ratio
    Aluísio JD Barros
    Vânia N Hirakata
    [J]. BMC Medical Research Methodology, 3 (1) : 1 - 13
  • [4] Hepatitis C virus (HCV) infection & risk factors for HCV positivity in injecting & non-injecting drug users attending a de-addiction centre in northern India
    Basu, Debasish
    Sharma, Arun Kumar
    Gupta, Sunil
    Nebhinani, Naresh
    Kumar, Vineet
    [J]. INDIAN JOURNAL OF MEDICAL RESEARCH, 2015, 142 : 311 - 316
  • [5] Centers for Disease Control and Prevention, 2022, HEP C FAQS PUBL
  • [6] Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review
    Degenhardt, Louisa
    Peacock, Amy
    Colledge, Samantha
    Leung, Janni
    Grebely, Jason
    Vickerman, Peter
    Stone, Jack
    Cunningham, Evan B.
    Trickey, Adam
    Dumchev, Kostyantyn
    Lynskey, Michael
    Griffiths, Paul
    Mattick, Richard P.
    Hickman, Matthew
    Larney, Sarah
    [J]. LANCET GLOBAL HEALTH, 2017, 5 (12): : E1192 - E1207
  • [7] Diaz T, 2001, AM J PUBLIC HEALTH, V91, P23, DOI 10.2105/AJPH.91.1.23
  • [8] Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
    Fattovich, G
    Giustina, G
    Degos, F
    Tremolada, F
    Diodati, G
    Almasio, P
    Nevens, F
    Solinas, A
    Mura, D
    Brouwer, JT
    Thomas, H
    Njapoum, C
    Casarin, C
    Bonetti, P
    Fuschi, P
    Basho, J
    Tocco, A
    Bhalla, A
    Galassini, R
    Noventa, F
    Schalm, SW
    Realdi, G
    [J]. GASTROENTEROLOGY, 1997, 112 (02) : 463 - 472
  • [9] Seroprevalence and burden of hepatitis C virus infection in WHO South-East Asia Region: A systematic review
    Goel, Amit
    Rewari, Bharat Bhushan
    Sharma, Mukta
    Konath, Nabeel Mangadan
    Aggarwal, Rakesh
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (06) : 964 - 972
  • [10] Burden of hepatitis C virus infection in India: A systematic review and meta-analysis
    Goel, Amit
    Seguy, Nicole
    Aggarwal, Rakesh
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (02) : 321 - 329